한국임상수의학회지 (Journal of Veterinary Clinics)

  • 제41권2호
  • /
  • Pages.95-100
  • /
  • 2024
  • /
  • 1598-298X(pISSN)
  • /
  • 2384-0749(eISSN)
한국임상수의학회 (The Korean Society of Veterinary Clinics)
권호 표지
DOI QR코드

DOI QR Code

Successful Management of Post-Attenuation Neurologic Signs and Portal Hypertension in a Dog with Congenital Portoazygos Shunt

  • Jin-Young Kim (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Kun-Ho Song (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Joong-Hyun Song (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University)
  • 투고 : 2024.01.10
  • 심사 : 2024.03.09
  • 발행 : 2024.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A 6-year-old neutered male Poodle with a body weight of 2.7 kg was diagnosed with a congenital extrahepatic portoazygos shunt presented with progressive hepatic encephalopathy. Five days after surgical attenuation, the patient showed post-attenuation neurological signs (PANS) such as generalized tonic-clonic seizure, dull mentation, and tremor. PANS were successfully managed with antiepileptic drugs, but third-space fluid accumulation (ascites and peripheral edema) and phlebectasia were newly identified, suggesting marked portal hypertension (PHT). Telmisartan, spironolactone, carvedilol, and prednisolone were sequentially administered. Three months after surgery, both abnormal clinicopathological values such as anemia and hypoalbuminemia, and clinical signs completely resolved. Herein, we report successful management strategies for PANS and PHT in a dog following surgical attenuation of a congenital portoazygos shunt.

키워드

과제정보

This study was supported by the National Research Foundation of Korea and funded by a grant from the Korean Government (NRF-2022R1G1A10036821131482092640101), and the Basic Science Research Program through the NRF, funded by the Ministry of Education (RS-2023-0021971031482092640001).

참고문헌

  1. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010; 51: 2214-2218.  https://doi.org/10.1002/hep.23689
  2. Buob S, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. J Vet Intern Med 2011; 25: 169-186.  https://doi.org/10.1111/j.1939-1676.2011.00691.x
  3. Cremers MI, Oliveira AP, Alves AL, Freitas J. Portal hypertensive gastropathy: treatment with corticosteroids. Endoscopy 2002; 34: 177. 
  4. Henderson AK, Webster CR. An in-depth look: disruption of the gastric mucosal barrier in dogs. Compendium 2006; 28: 340-357. 
  5. Lecavalier J, Fifle L, Javard R. Treatment of proteinuria in dogs with telmisartan: a retrospective study. J Vet Intern Med 2021; 35: 1810-1818.  https://doi.org/10.1111/jvim.16146
  6. Leung FW, Jensen DM, Guth PH. Endoscopic demonstration that vasopressin but not propranolol produces gastric mucosal ischemia in dogs with portal hypertension. Gastrointest Endosc 1988; 34: 310-313.  https://doi.org/10.1016/S0016-5107(88)71362-0
  7. Mullins RA, Escribano Carrera A, Anderson DM, Billet JP, Brissot H, Broome C, et al. Postattenuation neurologic signs after surgical attenuation of congenital portosystemic shunts in dogs: a review. Vet Surg 2022; 51: 23-33.  https://doi.org/10.1111/vsu.13729
  8. Ochoa-Sanchez R, Tamnanloo F, Rose CF. Hepatic encephalopathy: from metabolic to neurodegenerative. Neurochem Res 2021; 46: 2612-2625.  https://doi.org/10.1007/s11064-021-03372-4
  9. Rose LJ, Dunn ME, Allegret V, Bedard C. Effect of prednisone administration on coagulation variables in healthy Beagle dogs. Vet Clin Pathol 2011; 40: 426-434.  https://doi.org/10.1111/j.1939-165X.2011.00364.x
  10. Spinillo S, Golini L, Motta L. Brain MRI findings in a dog with late onset epileptic seizure after portosystemic shunt attenuation. Vet Rec Case Rep 2020; 8: e001159. 
  11. Stanton ME, Bright RM. Gastroduodenal ulceration in dogs. Retrospective study of 43 cases and literature review. J Vet Intern Med 1989; 3: 238-244.  https://doi.org/10.1111/j.1939-1676.1989.tb00863.x
  12. Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol 2010; 22: 905-911.  https://doi.org/10.1097/MEG.0b013e3283367a99
  13. Webster CRL, Center SA, Cullen JM, Penninck DG, Richter KP, Twedt DC, et al. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. J Vet Intern Med 2019; 33: 1173-1200.  https://doi.org/10.1111/jvim.15467
  14. Willems B, Villeneuve JP, Huet PM. Effect of propranolol on hepatic and systemic hemodynamics in dogs with chronic bile duct ligation. Hepatology 1986; 6: 92-97.  https://doi.org/10.1002/hep.1840060117
  15. Zheng L, Zhao Z, Lin J, Li H, Wu G, Qi X, et al. Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction. Eur J Pharmacol 2022; 915: 174713.